Evolus (EOLS) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evolus (EOLS) has outperformed Talphera (TLPH) over the past year, gaining 25.6% versus a loss of 18.2%. Over five years, EOLS leads with a +1.7% price change compared with -94.7% for TLPH. Evolus is the larger company by market cap ($515.2 million vs $56.1 million), about 9.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EOLS | TLPH |
|---|---|---|
| Share price | $7.80 | $1.08 |
| Market cap | $515.19M | $56.06M |
| 1-day change | +0.78% | +2.86% |
| YTD return | +17.29% | -5.26% |
| 1-year return | +25.60% | -18.18% |
| 5-year return | +1.69% | -94.71% |
| Forward P/E | 26.67 | — |
| EPS (TTM) | $-0.53 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.31 | $1.57 |
| 52-week low | $3.86 | $0.69 |
| Distance from 52-week high | -16.22% | -31.21% |
| Analyst consensus | none | none |
| Avg. price target upside | +92.31% | +189.81% |
| Average volume | 900.79K | 238.38K |
| Shares outstanding | 66.05M | 51.91M |
| Employees | 353 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Evolus is about 9.2 times larger than Talphera by market value ($515.19M vs $56.06M).
- EOLS has outperformed TLPH by 43.8 percentage points over the past year.
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
EOLS vs TLPH FAQ
Which is bigger, Evolus or Talphera?
Evolus (EOLS) is larger, with a market capitalization of $515.19M compared with $56.06M for Talphera (TLPH).
Which stock has performed better over the past year, EOLS or TLPH?
EOLS returned +25.60% over the past 12 months, compared with -18.18% for TLPH (price return, excluding dividends). Past performance does not predict future results.
Are Evolus and Talphera in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.